14.12.2009 • NewsLundbeck

Lundbeck Buys Neuronicon Danish pharmaceuticals group

H. Lundbeck has agreed to buy privately owned Danish biotechnology firm Neuronicon to gain technologies for treating brain damage. Lundbeck, whose main products are anti-depressants and which hopes to grow in neurological treatments. The financial details were not disclosed. At the same time, Lundbeck signed a deal to cooperate with University of Arhus scientists on further neurology research over the next three years, the company said. NeuronIcon was founded by scientists at the University of Aarhus and is based on research conducted there and at the University of Berlin, Lundbeck said.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.